BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1055 related articles for article (PubMed ID: 27431492)

  • 1. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
    BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
    Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
    Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
    Togashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Nakagawa K; Nishio K
    J Thorac Oncol; 2015 Jan; 10(1):93-101. PubMed ID: 25384171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
    Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
    Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
    Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
    Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R; Jiang H; Li J; Liu X; Xu H
    Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
    Moreira-Leite FF; Harrison LR; Mironov A; Roberts RA; Dive C
    J Thorac Oncol; 2010 Jun; 5(6):765-77. PubMed ID: 20421816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
    Wang H; Fei Z; Jiang H
    J Pharmacol Sci; 2017 Jul; 134(3):190-196. PubMed ID: 28757172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells.
    Song J; Zhong R; Huang H; Zhang Z; Ding D; Yan H; Sun E; Jia X
    Nutr Cancer; 2014; 66(4):682-9. PubMed ID: 24738693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
    Lee Y; Wang Y; James M; Jeong JH; You M
    Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.